Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine plus beta-blocker versus beta-blocker alone in persistent/permanent atrial fibrillation
ChiCTR1900026417Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ivabradine and carvedilol in Atrial fibrillation (AFib) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: ventricular rate, six-minute walking test and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
ivabradinecarvedilol
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR1900026417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026417.